Birch pollen-specific immunoglobulin E (Birch pollen IgE)

Birch pollen-specific immunoglobulin E (IgE) is a specialized class of antibodies produced by the immune system in sensitized individuals, primarily targeting the major birch allergen Bet v 1. These antibodies bind to high-affinity IgE receptors (FcεRI) on the surface of mast cells and basophils, effectively priming these cells for an allergic response. Upon subsequent exposure to birch pollen, the allergen cross-links the surface-bound IgE molecules, triggering the immediate release of inflammatory mediators such as histamine, which leads to symptoms of seasonal allergic rhinitis, conjunctivitis, and asthma. Additionally, these antibodies are responsible for oral allergy syndrome (OAS) due to cross-reactivity with homologous proteins in certain fruits and vegetables. Therapeutic interventions include the use of anti-IgE monoclonal antibodies like omalizumab, which sequester free IgE to prevent cellular sensitization, and allergen immunotherapy (AIT), which aims to reprogram the immune system to favor protective IgG4 antibodies over IgE. Monitoring the levels of birch-specific IgE is a standard diagnostic practice for identifying sensitization and evaluating the progress of desensitization treatments.

Other names

Bet v 1-specific IgEBirch-specific IgEAnti-birch pollen IgEAnti-Bet v 1 IgE

Drugs like omalizumab bind to the constant region (Cε3 domain) of free IgE, preventing its interaction with high-affinity receptors (FcεRI) on mast cells and basophils, which leads to receptor downregulation and reduced mediator release. Allergen immunotherapy (AIT), such as Itulazax, works by inducing immune tolerance through repeated exposure to controlled doses of birch pollen extract, shifting the immune response from IgE production toward protective IgG4 blocking antibodies and reducing the seasonal activation of IgE-producing plasmablasts.